Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Experimental cancer treatments Stories

2013-07-19 23:01:51

Jamie Reno, an award-winning journalist, cancer survivor and patient advocate, discussed on his blog in depth recent discoveries by a small biotech firm in San Diego that has made significant advancement in cancer research. San Diego, CA (PRWEB) July 19, 2013 Jamie Reno, an award-winning journalist, cancer survivor and patient advocate, discussed in depth the discoveries by a small biotech firm in San Diego that has been flying under the radar for the past decade. What’s the big...

2013-06-06 12:29:23

DUBLIN, June 6, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/wsl9sb/therapeutic) has announced the addition of the "Therapeutic Cancer Vaccines Market to 2019 - Pipeline Indicates Safer Treatments and Extended Patient Survival, though High Prices May Limit Uptake" [http://www.researchandmarkets.com/research/wsl9sb/therapeutic ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) There is...

2013-06-01 08:21:25

THOUSAND OAKS, Calif., June 1, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced detailed results from a pivotal Phase 3 trial evaluating talimogene laherparepvec in patients with unresected stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). The results will be presented as an oral presentation at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract No. LBA9008). The study met its primary...

2013-05-23 08:23:35

BUSAN, South Korea, May 23, 2013 /PRNewswire/ -- Pusan National University Yangsan Hospital, in collaboration with SillaJen, Inc., a private biotherapeutics and contract research company focused on research and development of targeted biological products for cancer, announced today a publication reporting the induction of functional anti-cancer antibodies in patients treated with the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). This research...

2013-05-22 08:29:34

Studies show superiority of AE37 among peptide cancer vaccines WORCESTER, Mass. and TORONTO, May 22, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced three presentations demonstrating the superiority of the AE37 breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations will be made at the annual meeting of the American Society of Clinical Oncology (ASCO)...

2013-05-22 08:27:21

CALGARY, May 22, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced preliminary results from its U.S. Phase 2 clinical trial in patients with metastatic melanoma using intravenous administration of REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 020). The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the Cancer...

2013-05-15 12:33:21

Interim Phase II Data and Follow-Up Analysis of Phase I Data Presented at Annual Meeting of the American Society of Gene and Cell Therapy DALLAS, May 15, 2013 /PRNewswire/ -- Today Gradalis, Inc. announced that FANG(TM), the company's tumor-based personalized cancer vaccine, elicits an immune response and delays time to recurrence in advanced stage ovarian cancer patients by more than one year compared to patients who received standard of care. Interim analysis of the Phase II...

2013-03-28 08:27:46

CALGARY, March 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC) (NASDAQ:ONCY) today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel in patients with metastatic stage IIIB, or stage IV, or recurrent SCCLC who are chemotherapy...

2013-03-19 20:23:25

THOUSAND OAKS, Calif., March 19, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). The study met its primary endpoint of durable response rate (DRR), defined as the rate of complete or partial response...

2013-03-13 17:50:29

Following several years of study, investigators have found more evidence that viral therapy to treat solid tumors can be enhanced by blocking the body´s natural immune response. Oncolytic viruses have shown promise as anticancer agents, with variations of the herpes simplex virus (HSV) among the most commonly used. However, many studies have shown that the effectiveness of viral therapy to eradicate tumors has not been as successful with patients as it has been in the lab. These...